Wells Fargo & Company Regenxbio Inc. Transaction History
Wells Fargo & Company
- $407 Billion
- Q2 2024
A detailed history of Wells Fargo & Company transactions in Regenxbio Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 34,844 shares of RGNX stock, worth $305,233. This represents 0.0% of its overall portfolio holdings.
Number of Shares
34,844
Previous 29,635
17.58%
Holding current value
$305,233
Previous $624,000
34.78%
% of portfolio
0.0%
Previous 0.0%
Shares
18 transactions
Others Institutions Holding RGNX
# of Institutions
199Shares Held
43.3MCall Options Held
58.9KPut Options Held
58.4K-
Black Rock Inc. New York, NY8.61MShares$75.4 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.11MShares$44.8 Million0.0% of portfolio
-
Redmile Group, LLC San Francisco, CA4.57MShares$40 Million3.49% of portfolio
-
Jpmorgan Chase & CO New York, NY3.01MShares$26.4 Million0.0% of portfolio
-
State Street Corp Boston, MA2.87MShares$25.2 Million0.0% of portfolio
About REGENXBIO Inc.
- Ticker RGNX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,230,000
- Market Cap $379M
- Description
- REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprie...